Zenas BioPharma, Inc. (ZBIO)
NASDAQ: ZBIO · Real-Time Price · USD
7.88
-0.29 (-3.55%)
Mar 31, 2025, 2:07 PM EDT - Market open

Zenas BioPharma Balance Sheet

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2024 FY 2023 FY 2022
Period Ending
Dec '24 Dec '23 Dec '22
Cash & Equivalents
319.7456.8667.21
Short-Term Investments
31.02--
Cash & Short-Term Investments
350.7756.8667.21
Cash Growth
516.93%-15.40%-
Prepaid Expenses
3.071.651.24
Restricted Cash
0.09--
Other Current Assets
21.3-
Total Current Assets
355.9259.868.44
Property, Plant & Equipment
1.191.011.8
Long-Term Deferred Charges
-1.39-
Other Long-Term Assets
12.865.974.33
Total Assets
369.9768.1874.58
Accounts Payable
17.145.45.82
Accrued Expenses
39.1617.0119.44
Current Portion of Leases
0.790.560.72
Current Income Taxes Payable
0.210.3-
Total Current Liabilities
57.2923.2625.97
Long-Term Debt
-20.3-
Long-Term Leases
0.220.260.81
Total Liabilities
57.5143.8226.78
Common Stock
0-0
Additional Paid-In Capital
699.654.651.03
Retained Earnings
-387.39-230.4-193.28
Comprehensive Income & Other
0.190.04-0.04
Total Common Equity
312.46-225.72-192.29
Shareholders' Equity
312.4624.3747.8
Total Liabilities & Equity
369.9768.1874.58
Total Debt
121.111.53
Net Cash (Debt)
349.7635.7465.68
Net Cash Growth
878.52%-45.58%-
Net Cash Per Share
26.5023.3444.02
Filing Date Shares Outstanding
41.81.581.55
Total Common Shares Outstanding
41.791.581.55
Working Capital
298.6336.5542.48
Book Value Per Share
7.48-143.15-124.11
Tangible Book Value
312.46-225.72-192.29
Tangible Book Value Per Share
7.48-143.15-124.11
Updated Mar 11, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q